Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
A Phase I/II Trial of AN-152 [AEZS-108) in Castration- and Taxane-Resistant Prostate Cancer
This is a research study for advanced prostate cancer. An experimental drug called AN-152 (also known as AEZS-108) will be used. The purpose of this study is to test the safety, tolerability and benefits of an experimental drug called AN-152.
The participants tumor will be tested for expression of this receptor (using an old biopsy). If the participants cancer does not have this receptor, participants will not be eligible to participant in this study.
AN-152 (AEZS-108) is administered intravenously (IV) over 2 hours and will be given at the specified dose every 3 weeks. Premedication with dexamethasone 8mg is recommended.
Participants will continue treatment until death, disease progression, unacceptable toxicity, participants refusal, treatment delay >3 weeks, or the completion of 6 cycles. Continuation beyond 6 cycles is left at the discretion of the study doctor.
The study is planned to last 2 years. Up to 55 (up to 18 for the Phase I portion, up to 37 for the Phase II portion).
研究概览
地位
研究类型
注册 (实际的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习地点
-
-
California
-
Los Angeles、California、美国、90033-0804
- University of Southern California
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion
- Histologically or cytologically confirmed prostate cancer
- Measurable disease on computer tomography (CT) scan or evaluable disease with an elevated prostate specific antigen (PSA)
- Documented progression on (a) at least one prior hormone treatment, which must have incorporated luteinizing hormone-releasing hormone (LH- RH)agonist therapy AND (b) at least one chemotherapy regimen, which must have been taxane based
- Progression may be demonstrated by PSA (defined by a 25% increase in the PSA from its most recent treatment nadir, confirmed with a second measurement at least 4 weeks later) or radiologic criteria (defined by radiologic documentation of a new lesion or a >= 20% increase in the sum of the diameters of previously noted measurable lesions)
- Palliative radiation therapy (RT) for metastatic disease is allowed only if =< 25% of total body bone marrow was irradiated and =< 35Gy administered to the pericardial area
- 28 days must have elapsed since completion of RT with bone marrow recovery
- Soft tissue disease irradiated in the prior 2 months may not be designated as measurable disease
- Eastern Cooperative Oncology Group (ECOG) performance score of 0-2
- Adequate bone marrow function, defined by ANC >= 1000/ul, hemoglobin >= 8.0 g/dL and platelet count >= 75,000/ ul
- Adequate renal function, defined by serum creatinine =< 1.5x the upper limit of normal (ULN)
- Adequate hepatic function, defined by bilirubin =< 1.5 mg/dL AND alkaline phosphatase =< 3x ULN for the reference lab (=< 5x ULN for patients with known hepatic metastases and no limit for patients with known bone metastases) AND AST and ALT =< 3x ULN (=< 5x the ULN for patients with known hepatic metastases)
- Must have recovered from acute and late effects of any prior surgery, radiotherapy or other anti-neoplastic therapy
- Patients or their legal representatives must be able to read,understand, and provide informed consent
- Men of childbearing potential must consent to use barrier contraception while on treatment and for 90 days thereafter
- Willingness to discontinue LH-RH analogue therapy and for the duration of the study
Exclusion
- Ongoing use of an LH-RH agonist (or antagonist)
- Patients who agree to stop LH-RH agonist therapy will be eligible but may need to wait until their required washout period is over
- Patients whose washout period is more than 6 weeks will not be eligible
- Duration of washout period varies with the formulation of the LH-RH agonist being used and should be 2 weeks after the next dose would be scheduled. Specifically: a) For patients receiving a monthly formulations of LH-RH agonist, 6 weeks must pass from the last dose before eligibility; b) For patients receiving a 3-month depot formulation of LH-RH agonist, 14 weeks must pass from the last dose before eligibility; c) For patients receiving a 4- month depot formulation of LH-RH agonist, 18 weeks must pass from the last dose before eligibility; d) For patients receiving a 6- month depot formulation of LH-RH agonist, 26 weeks must pass from the last dose before eligibility; e) For patients with an annual LH-RH implant, 2 weeks must pass after removal of the implant before eligibility
- Presence of an active infection or fever within 3 days of the first scheduled protocol treatment
- Presence of parenchymal brain metastases
- Patients with neurological symptoms must have a CT or magnetic resonance imaging (MRI)scan of the brain showing no metastases within 60 days of enrollment
- History of prior malignancy within the past 5 years with the exception of curatively treated basal cell or squamous cell carcinoma of the skin or superficial bladder
- Patients with known hypersensitivity to any of the components of AN-152 including doxorubicin and LH-RH agonists
- Patients who received radiotherapy within 4 weeks of entry
- Patients who received treatment with strontium-89 or samarium-153 are excluded, except prior samarium will be allowed provided it was administered more than 1 year ago and/or the patient has demonstrated the ability to receive cytotoxic chemotherapy without excess of myelosuppression after receiving samarium.
- Patients with a history of unstable or newly diagnosed angina pectoris, documented history of current serious arrhythmia or congestive heart failure or recent myocardial infarction (within 6 months of enrollment)
- Left ventricular ejection fraction (EF) < 50%
- Prior exposure to anthracyclines or anthracenediones including doxorubicin, daunorubicin, and mitoxantrone
- Major surgery within the last 2 weeks
- Receiving concurrent investigational therapy or have received investigational therapy within 30 days of the first scheduled day of protocol treatment (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication)
- Known HIV or hepatitis B or C infection
- Life expectancy < 3 months
- Presence of any other medical condition, including mental illness or substance abuse, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with interpretation of the results
- Prior treatment with AN-152
- Lack of ability or willingness to give informed consent
- Anticipated non-availability for study visits/procedures
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Arm I
Patients receive doxorubicin-GnRH agonist conjugate AEZS-108 intravenously (IV) over 2 hours once every 21 days (21 days = 1 cycle).
Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
|
相关研究
Correlative study
Given IV
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
Clinical benefit defined as non-progression with no dose-limiting toxicity or other toxicity requiring termination of treatment
大体时间:At 3 months up to 24 months
|
At 3 months up to 24 months
|
次要结果测量
结果测量 |
大体时间 |
---|---|
总生存期
大体时间:长达 2 年
|
长达 2 年
|
Time to overall disease progression
大体时间:Up to 24 months
|
Up to 24 months
|
Response for patients with measurable disease based on the Response Evaluation Criteria in Solid Tumors (RECIST)
大体时间:At 3 months up to 24 months
|
At 3 months up to 24 months
|
To assess the prostate specific antigen (PSA) response rate in patients treated with AN-152
大体时间:At 3 months up to 24 months
|
At 3 months up to 24 months
|
Time to PSA progression
大体时间:Up to 24 months
|
Up to 24 months
|
Number of participants with adverse events as a measure of safety and tolerability
大体时间:At 3 weeks up to 72 weeks
|
At 3 weeks up to 72 weeks
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
实验室生物标志物分析的临床试验
-
ORIOL BESTARD完全的
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)尚未招聘艾滋病毒感染 | 乙型肝炎
-
Hvidovre University HospitalElsassFonden终止
-
Fundació Sant Joan de DéuStanley Medical Research Institute; Parc Sanitari Sant Joan de Déu; Hospital Sant Joan de Deu完全的